Byetta Gains European Approval
This article was originally published in The Pink Sheet Daily
Lilly also pursuing diabetes treatment as monotherapy and in combination with thiazolidinediones in the U.S.
You may also be interested in...
After backfilling the supply channel using contract manufacturers, Lilly/Amylin resume promotions for the injectable type 2 diabetes product.
Lilly/Amylin'sByetta type 2 diabetes agent is "approvable" at FDA as a stand-alone therapy in conjunction with the April 29 approval of exenatide as an adjunct to other oral treatments, the firms said
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.